Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)

Stock Information for Arlington Asset Investment Corp Class A (new)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arlington Asset Investment Corp Class A (new)

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Class Action Filed Against Altimmune, Inc. (ALT) - October 6, 2025 Deadline to Join - Contact Levi & Korsinsky
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Altimmune, Inc. (ALT) Securities Fraud: Contact Berger Montague To Discuss Your Rights
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
October 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.